NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Specialty Chemicals · USD

BioNexus Gene Lab Corp. (BGLC) Stock Analysis

BioNexus Gene Lab Corp. (BGLC) is a Specialty Chemicals stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BGLC

$1.19

−$0.02 (−1.24%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BGLC with… →

BGLC Key Statistics

As of Oct 21, 2026
Trading
Open
$1.19
Previous Close
$1.21
Day's Range
1.19–1.20
52-Week Range
1.07–5.89
Volume
2.22K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.20
Valuation
Market Cap
$3.58M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.15
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.20
Financials (FY)
Revenue (FY)
$7.42M−21.93%
Net Income (FY)
−$2.98M
Profit marginThe share of revenue left as profit after all costs and taxes.
−82.36%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.93M
1-Year Return
−77.12%
Dividend and dates
Avg Volume
11.07K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BGLC closed at $1.19, −77.12% over 1 year.

BioNexus Gene Lab Corp. (BGLC) has a market capitalization of $3.58M.

In fiscal 2025, BGLC reported revenue of $7.42M.

BGLC Stock Return by Calendar Year

BioNexus Gene Lab Corp. (BGLC) return since Jan 2021: what $10,000 became

1 year
$10,000 $2,288
−77.12%
5 years
$10,000 $50
−99.50%
Since Jan 2021
$10,000 $45
−99.55%

If you had invested $10,000 in BioNexus Gene Lab Corp. (BGLC) at the close on January 8, 2021, the earliest close on record here, it would have been worth $45 at the close on October 21, 2026: −99.55% in total, −60.71% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−69.87%
2025+41.07%
2024−47.17%
2023−95.35%
2022−55.40%
2021−3.18%

As of October 21, 2026.

BGLC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$7.42M−$2.98M−40.2%
2024$9.51M−$1.60M−16.8%
2023$9.77M−$2.63M−26.9%
2022$10.93M−$355.97K−3.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$7.42M$1.09M−$3.16M−$2.98M−40.2%
2024$9.51M$1.29M−$1.96M−$1.60M−16.8%
2023$9.77M$1.33M−$3.08M−$2.63M−26.9%
2022$10.93M$1.26M−$291.18K−$355.97K−3.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BGLC Valuation vs Specialty Chemicals Median

Median of 70 stocks
MetricBGLCSpecialty Chemicals medianvs median
P/S ratio1.151.5928% below
Profit margin−82.36%2.70%85.1 pts below

Medians across 70 Specialty Chemicals stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values BioNexus Gene Lab Corp. (BGLC) at $3.58M. It is classified in the Specialty Chemicals industry, within the Basic Materials sector. Headcount on file is 19.

BGLC last closed at $1.19 on October 21, 2026. That is −$0.02 (−1.24%) against the previous close. The 52-week range on file runs from $1.07 to $5.89. The latest close sits 11.21% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $7.42M. Against the prior fiscal year total of $9.51M, that is a change of −21.93%. The same year closed with a net loss of $2.98M. Profit margin runs at −82.36%. That is 85.1 percentage points below the Specialty Chemicals median of 2.7%. Earnings per share on a trailing basis come to −1.2.

Across the 4 fiscal years on file, revenue moves from $10.93M in 2022 to $7.42M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 1.15 times revenue. On price-to-sales that is 28.12% below the Specialty Chemicals median of 1.59. The medians here are taken across 70 Specialty Chemicals companies that report the metric.

The reported beta is 2.2. Daily returns over the trailing 5 years annualize to a volatility of 266.42%. The trailing one-year total return is −77.12%. Measured over 5 years, that is −65.40% a year compounded.

Growth & Income

No dividend is on file for BGLC.

2026 is still running; the total return is −69.87% year to date. The strongest complete calendar year on file is 2025 at +41.07%; the weakest is 2023 at −95.35%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

BioNexus Gene Lab Corp. (BGLC) operates in the Specialty Chemicals industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BioNexus Gene Lab Corp. BGLC $3.58M —
Linde plc LIN $230.75B 32.3
The Sherwin-Williams Company SHW $81.88B 31.1
Ecolab Inc. ECL $80.76B 38.7

The Specialty Chemicals industry average P/E ratio is 28.3x. BioNexus Gene Lab Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Specialty Chemicals Stocks

LIN

Linde plc

$230.75B

 SHW

The Sherwin-Williams Company

$81.88B

 ECL

Ecolab Inc.

$80.76B

 APD

Air Products and Chemicals, Inc.

$67.40B

 PPG

PPG Industries, Inc.

$24.49B

 IFF

International Flavors & Fragrances Inc.

$23.23B
View all Specialty Chemicals stocks →

Popular Basic Materials Stocks

BHP

BHP Group Limited

$211.50B

 SCCO

Southern Copper Corporation

$167.24B

 RIO

Rio Tinto Group

$141.37B

 NEM

Newmont Corporation

$123.47B

 FCX

Freeport-McMoRan Inc.

$98.94B
View all Basic Materials stocks →

About BioNexus Gene Lab Corp.

BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Visit website →